NXTG.TA TLV
Nextage Therapeutics Ltd
1W: +8.4%
1M: +20.5%
3M: -11.0%
YTD: -12.0%
1Y: -62.6%
3Y: -58.3%
5Y: -93.0%
₪38.70 ($0.13)
-0.10 (-0.26%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$413K
-52.9% ▼
5Y CAGR: +6.8%
Gross Profit
$76K
-66.2% ▼
5Y CAGR: -18.2%
Operating Income
-$3M
+13.7% ▲
Net Income
-$3M
+15.4% ▲
EPS (Diluted)
$-0.11
+15.4% ▲
EBITDA
-$3M
+16.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $191K | $91K | $0 | $876K | $413K |
| YoY Growth | -35.7% | -52.4% | -100.0% | +0.0% | -52.9% |
| Cost of Revenue | $154K | $75K | $57K | $651K | $337K |
| Gross Profit | $37K | $16K | -$57K | $225K | $76K |
| Gross Margin | 19.4% | 17.6% | — | 25.7% | 18.4% |
| R&D Expenses | $777K | $2M | $2M | $976K | $130K |
| SG&A Expenses | $833K | $1M | $4M | $1M | $1M |
| Operating Expenses | $16M | $5M | $6M | $4M | $4M |
| Operating Income | -$17M | -$7M | -$6M | -$4M | -$3M |
| Operating Margin | -8929.8% | -7825.3% | — | -455.1% | -832.7% |
| Interest Expense | $166K | $212K | $25K | $50K | $27K |
| Income Before Tax | -$16M | -$8M | -$6M | -$4M | -$3M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$16M | -$8M | -$6M | -$4M | -$3M |
| Net Margin | -8359.2% | -8492.3% | — | -442.8% | -794.9% |
| EPS (Diluted) | $-1.40 | $-0.30 | $-0.21 | $-0.13 | $-0.11 |
| EBITDA | -$16M | -$8M | -$6M | -$4M | -$3M |
| Shares Outstanding | 11M | 26M | 28M | 29M | 29M |